From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Human
Target CSF2
Clinical data
ATC code
  • none
CAS Number
  • none
 NYesY (what is this?)  (verify)

Namilumab (alternative identifier MT203) is a human monoclonal antibody (class IgG1 kappa) that targets granulocyte macrophage-colon stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis.[1][2][3] Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis[4] and rheumatoid arthritis.[5][6]

Namilumab was produced by Micromet Inc and is under development by Takeda Pharmaceuticals International.[3][7]


  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4). 
  2. ^ "Meeting Abstract: Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)". 
  3. ^ a b "Namilumab - AdisInsight". Retrieved 2017-03-24. 
  4. ^ "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis - Full Text View -". Retrieved 2017-03-24. 
  5. ^ "A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate - AdisInsight". Retrieved 2017-03-24. 
  6. ^ "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) - Full Text View -". Retrieved 2017-03-24. 
  7. ^ "Takeda clinical trials summary:Namilumab".